STOCK TITAN

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
NOWDiagnostics (NOWDx) appoints Dr. Stephen S. Tang, former head of OraSure Technologies, as the chairman of the board. Dr. Tang brings extensive experience in the medical diagnostic industry, having led OraSure Technologies to significant growth and product development during his tenure.
Positive
  • None.
Negative
  • None.

Former Head of OraSure Technologies Joins at Key Stage Leading up to Company’s Product Launch

SPRINGDALE, Ark.--(BUSINESS WIRE)-- NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/

NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)

NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)

Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDAQ: OSUR), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO, chairman of the board of directors, and chairman of the compensation committee. During his tenure as president and CEO, OraSure launched more FDA-cleared products, vastly expanded its sales, and developed and acquired more innovative products and services in its history.

“I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board,” said Dr. Tang. “For many years, the medical diagnostic industry has sought to bring in-home tests from the lab to regulatory approval and widespread consumer use. More than ever, NOWDx brings us all closer to fulfilling that vision for better, more accessible healthcare for everyone with its in-home test, with in-home results in minutes platform. I am honored to join a talented and engaged board of directors to assist a highly capable and experienced team led by CEO Rob Weigle.”

Prior to leading OraSure, Dr. Tang was president and CEO of the University City Science Center in Philadelphia, the mid-Atlantic region's premier innovation hub for life science companies. He also led Olympus America's Life Sciences Group, which included laboratory diagnostic, microscope, and translational research instruments. He earned his BS in Chemistry from the College of William & Mary, MS and Ph.D. in Chemical Engineering from Lehigh University, and an MBA for Executives from The Wharton School of Business at the University of Pennsylvania. In 2016, he was awarded a Doctor of Humane Letters (honoris causa) from Thomas Jefferson University (formerly Philadelphia University) and the Wagner Free Institute of Science.

“We are extremely pleased to welcome Stephen as chairman of the board, and particularly fortunate for his expert understanding of the impact that at-home diagnostics can have in early detection of diseases. His deep knowledge in the diagnostics space and his impactful leadership at OraSure will be invaluable as we await FDA authorization for our first at-home test for syphilis and set up our entire product portfolio for commercial launch,” said Rob Weigle, CEO of NOWDiagnostics. “In addition, his broad leadership experience in research and life sciences roles will help to guide our strategic vision of becoming the go-to choice for at-home and point-of-care diagnostics.”

Michele Colucci, founder and managing partner at DigitalDx, stated, “As a diagnostic fund, we at DigitalDx Ventures are incredibly excited to welcome Steve Tang to the NOWDx board of directors as its board chair. Very few professionals have the depth of experience in the diagnostic industry as Steve does, much less his level of expertise in the boardroom. His steady, supportive hand, collaborative approach, and revenue focus are exemplary and exactly what is needed to harness the incredible talent in the C-suite and complement the existing composition of the board. Boards are often like a puzzle, and in this context we'd say he's the perfect fit.”

“We are very much looking forward to the leadership and strategic direction that Stephen Tang will provide NOWDx,” stated Jeremy Wilson, co-founder of NOWDx and co-managing partner of private equity firm NewRoad Capital Partners. “With his heavy-hitting expertise, he will position the company very well for future growth, while creating impact and innovation in the diagnostics industry.”

Dr. Tang currently serves on the Boards of Directors of several nonprofit organizations, including the William & Mary Foundation, Population Services International, Lehigh University, Team Pennsylvania Foundation, and Life Sciences Pennsylvania.

About NOWDiagnostics (NOWDx)

NOWDx develops and manufactures “Touch to Test” over-the-counter and point-of-care diagnostic tests that yield results in minutes. Its patented approach allows for virtually any immunological assay to be accurately performed onsite in one step using a tiny amount of capillary blood or, in some cases, saliva. NOWDx envisions a world where people have greater access to in-home testing with in-home results - in minutes. It is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.

Please visit nowdx.com for more information or follow the company on LinkedIn.

Todd Grice

NOWDx

todd.grice@nowdx.com

717.380.9400

Alex Romero-Wilson

Health+Commerce

alexander@healthandcommerce.com

Source: NOWDiagnostics

Dr. Stephen S. Tang, former head of OraSure Technologies.

Dr. Tang led OraSure Technologies, a pioneer in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO.

Under Dr. Tang's leadership, OraSure Technologies launched more FDA-cleared products, expanded its sales, and developed innovative products and services.
Orasure Technologies Inc.

NASDAQ:OSUR

OSUR Rankings

OSUR Latest News

OSUR Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Bethlehem

About OSUR

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo